Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polycythemia Vera 3 Thrombocythemia, Essential 2 Philadelphia Chromosome 2 Neoplasm Metastasis 2 Myeloproliferative Disorders 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Brain Neoplasms 2 Skin Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Leukemia 1 Glioma 1 Colonic Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1 Breast Neoplasms 1 Blast Crisis 1

Interventions

Fluorouracil 87 Leucovorin 78 Oxaliplatin 77 Irinotecan 76 Bevacizumab 50 Cetuximab 42 Capecitabine 42 Panitumumab 17 Folfox protocol 16 Floxuridine 11 Chemotherapy, Adjuvant 11 regorafenib 10 IFL protocol 10 Nivolumab 9 Drug Therapy 9 trifluridine tipiracil drug combination 8 Surgical Procedures, Operative 8 Neoadjuvant Therapy 8 sargramostim 7 pembrolizumab 7 XELOX 7 Specimen Handling 7 Biopsy 7 Trastuzumab 6 Radiotherapy 6 Magnetic Resonance Spectroscopy 6 HMPL-013 6 tislelizumab 5 encorafenib 5 Trifluridine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colonic Neoplasms × peginterferon alfa-2a × Clear all

NCT04798612 2023-08-18

IPOS

Zealand University Hospital

Phase 2 Unknown

Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡